Regenerative Medicine | 8/14/2026 | Tsuyoshi Hadano

Japan's MHLW Issues Regenerative Medicine Improvement Orders: Five Operational Checks for Clinics

Five practical checks for clinics after Japan's MHLW published improvement orders involving regenerative medicine providers and cell-processing operations.

On July 31, 2026, Japan’s Ministry of Health, Labour and Welfare (MHLW) announced administrative actions under the Act on the Safety of Regenerative Medicine involving managers of regenerative medicine providers and operators engaged in processing specified cellular products.

The announcement is important because the issues were not limited to whether the required documents existed. The MHLW materials describe concerns about who was actually making treatment decisions, whether adverse events were reported, and whether manufacturing and quality controls were being managed appropriately.

This article separates the facts described in the public announcement from practical operational points that medical institutions may want to review.

What the MHLW announced

According to the MHLW’s July 31, 2026 publication, administrative measures were taken against two managers of medical institutions and one operator involved in processing specified cellular products, while an improvement request was issued to an operator in South Korea.

One of the matters that led to the investigation involved a patient who deteriorated during administration of regenerative medicine in March 2026 and was subsequently confirmed dead. The MHLW issued an emergency order and conducted on-site inspections, later reporting that multiple legal violations had been identified. The cause of death was still under investigation at the time of publication.

The public materials also describe another case in which a patient required hospitalization after receiving regenerative medicine, but the required disease or adverse-event report had not been submitted.

Five operational points clinics should review

Based on the matters identified in the MHLW materials, the following five areas deserve particular attention.

1. Is the medical institution itself deciding whether and how treatment should be provided?

The public materials describe a structure in which patient selection, treatment dates, treatment intervals, and cell numbers were effectively determined based on lists and instructions prepared by a third party, with limited independent involvement by the medical institution.

Even when certain tasks are outsourced, a clinic should confirm that medical decision-making itself has not effectively been delegated to an outside business operator.

2. Is the basis for patient eligibility recorded in the medical record?

The MHLW materials state that some medical records did not sufficiently document the patient’s chief complaint, symptoms, or how the patient met the selection and exclusion criteria in the treatment plan.

Operationally, a third party reviewing the record later should be able to understand why the clinician judged that this regenerative medicine was appropriate for that patient.

3. Does the adverse-event reporting workflow actually function?

The investigation identified a case in which a health problem requiring hospitalization had occurred but the applicable report had not been made.

Clinics should review what happens after an abnormal event is recognized: who confirms it, who determines whether reporting is required, and which procedure is followed. The formal reporting obligation and the clinic’s internal workflow need to connect in practice.

4. Are instructions to and checks on outsourced cell-processing operators effective?

The public materials describe circumstances in which the medical institution could not be said to have provided effective necessary instructions regarding the manufacture of specified cellular products, and where adequate confirmation of proper manufacturing before administration was lacking.

The existence of a contract alone is not enough. Clinics should examine whether manufacturing conditions, quality control, information sharing when changes occur, and acceptance checks are actually functioning operationally.

5. Does the relationship with outside businesses undermine the clinic’s medical independence?

The announcement describes extensive involvement by third parties in areas including treatment fees, patient selection, treatment planning, and administration conditions.

The core issue is not simply whether an outside partner is involved. The question is whether the relationship has effectively shifted medical judgment or management responsibilities away from the medical institution.

A practical checklist for clinics

In light of the cases described by the MHLW, clinics providing regenerative medicine may find it useful to review at least the following:

Whether the approved treatment plan matches the actual clinical workflow
Whether patient eligibility decisions and their rationale are documented in the medical record
Whether the workflow for adverse-event or disease reporting is clear and operational
Whether instructions to and checks on outsourced cell-processing operators are actually being carried out
Whether an outside business is effectively deciding patient selection or treatment conditions
Whether responsible persons and review procedures are understood inside the clinic

These are practical review points derived from the MHLW publication. They should not be interpreted as an assertion that every item constitutes the same legal obligation for every medical institution. Individual treatment plans, contracts, and legal requirements should be checked against primary sources and, where necessary, qualified specialists.

HDN’s perspective: focus on who is actually making the decision

One of the most important implications of the publication is that the issue is not limited to whether policies, forms, and SOPs exist. The actual operation matters: who selects the patient, who determines the treatment, and who confirms manufacturing conditions.

When reviewing a clinic’s system, it can be more useful to map the real patient journey, medical decisions, and interactions with outsourced providers in chronological order than simply to add more policies. This often makes unclear responsibilities easier to identify.

HDN supports clinics with operational workflow design, patient journey design, and implementation. Where a legal determination is required, we recommend reviewing the matter with professionals experienced in Japanese healthcare law.

Reference

Ministry of Health, Labour and Welfare, “Improvement Orders and Other Measures under the Act on the Safety of Regenerative Medicine” (July 31, 2026)

This article is an operational summary prepared by HDN based on public materials from Japan’s Ministry of Health, Labour and Welfare. For individual legal, clinical, or treatment-plan determinations, consult the applicable laws, authorities, and qualified professionals.